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creativecommons.org/licenses/by-nc-nd/Abstract Our current mycosis fungoides (MF) and Se´zary Syndrome (SS) staging system in-
cludes blood-classification from B0-B2 for patch/plaque/tumour or erythroderma based on
manual Se´zary counts but results from our EORTC survey confirm these are rarely performed
in patch/plaque/tumour MF, and there is a trend towards using flow cytometry to measure
blood-class. Accurately assigning blood-class effects overall stage and the ‘global response’
used to measure treatment responses in MF/SS and hence impacts management. The EORTC
Cutaneous Lymphoma Task Force Committee have reviewed the literature and held a Work-
shop (June 2017) to agree a definition of blood-class according to flow cytometry.
No large study comparing blood-class as defined by Se´zary count with flow cytometry has
been performed in MF/SS. The definition of blood-class by flow cytometry varies between
publications. Low-level blood involvement occurs in patch/plaque/tumour much less thanf Dermatology, University Hospital Birmingham, Birmingham, B15 2TH, UK. Fax: þ44 121 460 5845.
b.nhs.uk (J.J. Scarisbrick).
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
J.J. Scarisbrick et al. / European Journal of Cancer 93 (2018) 47e5648erythroderma (p < 0.001). The prognostic relevance of blood involvement (B1 or B2) in patch/
plaque/tumour is not known. Studies have not shown a statistically worse difference in prog-
nosis in erythrodermic MF patients with low-level blood involvement (IIIB) versus those
without (IIIA), but Sezary patients who by definition have a leukaemic blood picture (staged
IVA1 or higher) have a worse prognosis.
For consistency flow, definition for blood-class must be an objective measurement. We pro-
pose absolute counts of either CD4þCD7-or CD4þCD26-where B0<250/mL, B1 Z 250/ml
e<1000/mL and B21000/mL plus a T-cell blood clone. Fluctuations between B0 and B1
should not be considered in the treatment response criteria until further prognostic informa-
tion is known.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Blood-classification was introduced into the TNM
classification of mycosis fungoides (MF) and Sezary
syndrome (SS) in the 2007 revision [1]. Blood-class
from B0-B2 was defined using manual Se´zary counts
based on morphology, but these are highly subjective
and have never been validated in a multicentre pro-
spective international study. B2 was defined as 1000/
mL Se´zary cells and, in those with erythroderma and a
positive blood T-cell clone identical to skin, were the
diagnostic criteria for SS. B1 was defined as greater
than 5% circulating Se´zary cells (as a percentage of
circulating lymphocytes) using a manual Se´zary count
(on a peripheral blood smear) to differentiate those
patients with low-level blood involvement from B0;
thereby defining B0 as 5% circulating Se´zary cells [1].
Blood involvement may occur in MF and SS especially
in advanced stages of disease notably erythroderma
(defined as >80% of skin involved), but blood
involvement may also occur in patch/plaque or tumour
MF. In erythroderma, blood-class defines the patients
who do not reach the criteria for SS stage (IVA1) as
stage IIIA (blood-class;B0) or stage IIIB (blood-class;
B1). Blood-class is similarly recorded for patch/plaque
or tumour MF, but B0-1 does not change stage,
whereas B2 is designated IVA1 independent of the level
of skin involvement. Circulating Sezary cells have
recently been shown to have a diverse phenotype from
skin Sezary cells despite demonstrating clonality with
skin-derived Sezary cells showing a more advanced
maturation pattern with differences in cytokine/che-
mokine receptor expression [2]. CD4þCD7- and
CD4þCD26-subsets are the most commonly used to
identify the neoplastic population in MF/SS. However,
partial loss of these markers may occur on benign T-
lymphocytes with ageing, in inflammatory dermatoses
or following therapy [1e5]. Other aberrant phenotypes
may also occur but are less common.
As there is no objective definition of blood-class using
flow cytometry, centres have adopted different defini-
tions for publications. The EORTC is leading aProspective Cutaneous Lymphoma International Prog-
nostic Index study (PROCLIPI study) in early-stage MF
which collects staging, survival and treatment data. For
the TNMB stage to be comparative and consistent in
future publications, an agreement for the definition of
blood-class is required. Furthermore, as response in
blood is considered as part of treatment response used
for clinical trials in MF/SS, it is essential that there is a
universal objective definition. Here, we review the liter-
ature and report on our EORTC Workshop defining
blood-class in MF/SS.
2. Material and methods
We reviewed the literature of blood involvement in MF/
SS using flow cytometry, through an internet search of
relevant medical databases (e.g. PUBMED, MEDLINE)
as well as a targeted search of relevant professional
bodies and their guidelines (e.g. EORTC, ISCL (Inter-
national Society for Cutaneous Lymphoma), UK-CLG
(UK-Cutaneous Lymphoma Group). We performed an
EORTC survey of centres detailing their current practice
for measuring blood involvement by flow cytometry and
reviewed preliminary PROCLIPI data.
Following discussions at the EORTC Annual Gen-
eral Meeting (April, 2017), an EORTC Blood Classifi-
cation Workshop to review the literature and define
blood-class using flow cytometry was held (June 2017).
3. Results
3.1. Workshop discussion and interpretation of current
staging and response criteria
A comprehensive literature review confirms that there is
no objective universal definition of blood-class in MF/
SS according to flow cytometry. The adoption of CD26-
cells in the assessment of blood involvement in MF/SS
followed the work by Bernengo et al. [3] which
compared the percentage of CD4þCD26-% in 103 MF/
SS patients with blood-class defined by Se´zary counts.
Of 151 MF patients, 14 (9%) had B1 (5% Se´zary cells
Table 1
Comparison of blood-class measurements according to flow cytometry in MF/SS.
Blood-class
according to flow
B0 B0 comments B1 B1 Comments B2 B2 comments
Vonderheid et al
2002 [3]
Not defined by flow Not defined by flow A CD4/CD8 ratio of 10
or more due to an
increase in CD3 or CD4
cells by flow cytometry
or aberrant expression
of pan T-cell markers
(CD2, CD3, CD4, CD5)
by flow cytometry.
Deficient CD7
expression on T-cells or
expanded CD4þCD7-
40%
Olsen et al, 2007
[1]
Not defined by flow Not defined by flow TCR clone plus
expanded CD4þ or
CD3 population with
CD4:CD8>10 or
expanded CD4þ with an
abnormal phenotype
including loss of CD7-
or CD26- (40%
CD4þ/CD7- or 30%
CD4þ/CD26-)
Definition of expanded
CD3 or CD4 population
not defined
Olsen et al, 2011
[4]
Absence of a clone and
either fewer than 20%
Se´zary cells or fewer than
250 Se´zary cells/
mL.[Vonderheid 2003 24]
Data suggest that a normal
value for CD4þCD26- or
CD4þCD7- cells by flow
cytometry is lower than
15%. Based on an upper
limit of normal value of
1600/mL for CD4 cells in the
blood, an absolute count of
lower than 250/mL CD4þ/
CD26- or CD4þCD7- cells
would appear to be a
normal value for these CD4
subsets and could also be
used to define the absence of
or normalisation of blood
involvement (B0)
From text, not included in
any table. Definition of B0
is given twice
1.A normal value for
CD4þCD26- or
CD4þCD7- cells by flow
cytometry is lower than 15%
and
2. An absolute count of
lower than 250/mL CD4þ/
CD26- or CD4þCD7- cells
would appear to be a
normal value
250-<1000 mL As default with B0 as
<250 mL and B2 as  1000/
mL
1000/mL cells with
positive clone; one of the
following can be
substituted for Se´zary
cells: CD4/CD8 10,
CD4þCD7- cells 40%
or CD4þCD26- cells
30%
Not specified in Table 1
but presume
substitution of 1000/
mL cells with flow
measurements only
defines B2 in patients
with an expanded CD4
population.
(continued on next page)
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Table 1 (continued )
Blood-class
according to flow
B0 B0 comments B1 B1 Comments B2 B2 comments
Benton et al,
2014 [19]
<500 Se´zary cells/mL Assessed by flow cytometry 500-1000 Se´zary cells/mL Assessed by flow cytometry >1000 Se´zary cells/mL
or 35% of lymphocytes
as CD4þCD26- or
CD4þCD7-
Assessed by flow
cytometry
Gibson et al 2016
[25]
CD4:CD8>5, >20%
CD4þ/CD7- or >20%
CD4þ/CD26-
B1 flow definition
determined without
prognostic data
Vonderheid et al
2017 [9]
<30% CD4þCD26- and
<1000/mL
30% CD4þCD26- and
<1000/mL
CD4þCD26- 1000/mL
NCCN
Guidelines
2017 [28]
Absence of significant blood
involvement: 5% of
peripheral blood
lymphocytes or <250/mcL
are atypical (Se´zary) cells
or < 15% CD4þ/CD26dor
CD4þ/CD7dcells of total
lymphocytes
Low blood tumour burden:
>5% of peripheral blood
lymphocytes are atypical
(Se´zary) cell or  15%
CD4þCD26 e or
CD4þCD7 e of total
lymphocytes but do not
meet the criteria of B0 or B2
High blood tumour
burden: 1000/mcL
Se´zary cells (CD4þ/
CD26 e or CD4þ/CD7
e cells by flow
cytometry) or CD4/
CD8  CD8  10 or
40% CD4/CD7 eor
30% CD4þ/CD26 e
cells of total
lymphocytes
PROCLIPI <250/mL CD4þCD7- or
CD4þCD26- cells/mL
The absolute value of <250/
mL was chosen as defined in
Clinical Endpoints paper
and is the approximately
15% or an expanded CD4þ
level of 1600/mL. 15% has
been suggested as the upper
limit of normal for
CD4þCD7- or
CD4þCD26- cells.
250/mL - <1000/mL
CD4þCD7- or
CD4þCD26- cells/mL
1000/mL CD4þCD7-
or CD4þCD26- cells/mL
(or other aberrant
phenotype) plus
evidence of a relevant T-
cell clone in blood
(identical to skin clone)
1000/mL was the
original definition for B2
using manual Se´zary
count and B2 was shown
to have a poorer
survival in advanced-
stage patients compared
with B0 [17]
Abbreviations: B0, absolute counts of either CD4þCD7-or CD4þCD26-are <250/mL cells; B1, CD4þCD7-or CD4þCD26-counts are between 250/mLe<1000/mL cells; B2, CD4þCD7-cells or
CD4þCD26-cells or other aberrant phenotype 1000/mL in the presence of a relevant T-cell clone in blood; MF, mycosis fungoides; SS, Se´zary syndrome.
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J.J. Scarisbrick et al. / European Journal of Cancer 93 (2018) 47e56 51but <1000). 13 of 14 of these patients had >30%
CD4þCD26-cells and none of the patients with B0 MF
or any of the 88 patients with benign inflammatory
erythroderma or healthy controls had >30%
CD4þCD26-cells. CD4þCD26-% was greater than 40%
in all 52 SS patients [3]. A statistically significant direct
relationship between CD26-percentage values and the
Se´zary cell count percentage was found in B1 and B2
patients (p < 0.001).
The number of centres performing manual Se´zary
counts declined as this was highly subjective and
required considerable experience with flow cytometry
becoming the more popular alternative for measuring
blood involvement in MF/SS. The ISCL suggested that
B2 may be defined by flow in patients with a T-cell clone
in blood as 1) expanded CD4þ/CD3þ cells with CD4/
CD8 ratio of 10, (2) expanded CD4þ cells with
abnormal immunophenotype including loss of CD7/
CD26 (40% CD4þCD7-or 30% CD4þCD26-), but
no definition of expanded CD4þ cells was given [4]. This
led to different interpretation for measuring B2 blood-
class between centres. Furthermore, no definition of
B0/B1 using flow cytometry was provided. The use of
CD4/CD8 ratio>10 to classify B2 is reliant on the ab-
solute CD8 count which may be reduced by treatment
resulting in a raised ratio with a normal CD4 count and
the relevance of this has not been tested. We found a
CD4/8 > 10 in 2e10.5% of patients with patch/plaque/
tumour MF but in 52.2% with erythroderma (Table 2).
TCR clonality in blood should be recorded as a/b
alongside blood-class but does not alter the overall stage
or blood response [5]. For T-cell clonality to be relevant,
it must be identical to the skin T-cell clone as blood
clones may occur in the elderly population with un-
known significance. The prognostic significance of a
TCR blood clone in MF is not yet proven [6]. Agar et al.
found T-cell clonality to be of prognostic importance in
B0 patients (p < 0.001) but not B1. A relevant T-cell
blood clone is a diagnostic criterion for Sezary. However
according to our EORTC survey (Table 3), blood tests
performed at centres in different stages of MF/SS found
only 7/31 (23%) centres are performing TCR studies on
all stages of MF/SS patients.
Clonality may be tested using PCR with biomed 2 but
PCR is not quantitative. Clonality using V beta anti-
bodies allows quantification of the T-cell clone but at
present only covers around 70% of the T-cell receptor
repertoire. Currently, clonality using V beta antibodies
is not routinely performed and remains expensive. High
throughput sequencing is a novel technique which al-
lows near to 100% of T-cells clones to be identified and
is quantitative but is only available in highly specialised
centres, and costs are likely to be prohibitive as a routine
diagnostic test. Yoo et al. [8] found an identical pe-
ripheral T-cell clone in 2/30 (6.7%) patients with T1/T2,
5/13 (38.4%) with T3 and 9/14 (64.3%) with T4 disease.
Our preliminary PROCLIPI data also found anincreased likelihood of a relevant T-cell clone in blood
with increasing T class 1 to 3 despite the lack of asso-
ciation of increasing blood-class with T-classes Table 2.
The Clinical Endpoints [2011], which introduced
measuring response to treatment in skin, blood, node
and viscera in MF/SS for use in clinical trials, further
defined B0-2 using flow cytometry [5], Table 1. How-
ever, the criteria for blood-class are open to interpreta-
tion, normal flow measurements for B0 were defined as
CD4þCD26-or CD4þCD7-cells <250/mL or < 15% by
flow cytometry and studies adopted different definitions
for B0-2 (Table 1). Furthermore, these values are arbi-
trary and not backed up by prospective multicentre in-
ternational studies.
Our survey of 31 EORTC sites confirmed flow
cytometry to be the preferred method of tracking blood
involvement (Table 3). Few centres are performing
manual Se´zary counts on all MF/SS patients, and 7
centres (23%) no longer perform manual counts. Flow
cytometry is performed in all centres but frequently
restricted to advanced stages. Only 11 sites (35%) of sites
perform flow on all stages of MF/SS (Table 3). A recent
publication from the United States found the number of
sites performing Se´zary counts was just over half (51%),
however, >90% measured CD4þCD7-cells [9].
After interim analysis of PROCLIPI blood data, it
was striking that blood involvement through T class
1e3 was similar (Table 2), but blood involvement in
erythrodermic disease is significantly higher p < 0.001.
We therefore divided our discussions into blood-class in
patch/plaque or tumour MF and erythroderma.
3.2. Blood-class B0-B2 in patch/plaque or tumour MF
patients
Most patients with early-stage MF are B0, but B1 and
B2 may be seen in early-stage MF with Talpur et al. [10]
reporting 2.0% of stage IA with B1 and 0.6% with B2
[6] using a definition of B1 (aleukaemic >500
and < 1000 cells/mL), or B2 (leukaemic >1000 cells/mL)
with no significant difference in the survival between B0
and B1 in early-stage MF patients.
Previously, Harmon et al. [11] reported on
CD4þCD7-in the blood of 31 patients with benign der-
matoses, 35 patients who had CTCL and 16 normal
controls. There was no statistical difference between the
mean % CD4þCD7-circulating cells for the normal
control (5.8%) or the benign dermatoses (9.3%; pZ 0.13)
nor between benign dermatoses and MF (pZ 0.80). The
patients with pre-SS and SS had a higher mean percent-
age of CD4þCD7-cells (22.4% and 35.5%, respectively)
than patients with benign dermatoses (p < 0.01). In the
retrospective study on 1422 MF patients reported by the
Italian Study Group for Cutaneous Lymphoma [12],
among patients with stage IVA1, only 5% had T1 and
28% T2. Recently, Vonderheid and Hou [13] reported
B2 as defined by Se´zary cells 1000/mL in 7 of 373
Table 2
Preliminary PROCLIPI data from Europe showing blood-class, nodal-class, flow cytometry, serum LDH and blood T-cell clone according to T
class.
T1a T1b T2a T2b T3 T4
No. patients 125 97 112 152 56 81
B0 121 (96.8%) 90 (92.8%) 102 (91.1%) 138 (90.8%) 52 (92.9%) 23 (28.4%)
B1 4 (3.2%) 5 (5.2%) 9 (8.0%) 10 (6.6%) 4 (7.1%) 18 (22.2%)
B2 0 2 (2.1%) 1 (0.9%) 4 (2.7%) 0 40 (49.4%)
N0 123 (98.4%) 93 (95.9%) 110 (98.2%) 129 (84.9%) 38 (67.9%) 39 (48.4%)
Nx 2 (1.6%) 1 (1.1%) 0 15 (9.9%) 10 (17.9%) 21 (26.0%)
N1-2 0 3 (3.1%) 2 (1.8%) 3 (2.0%) 5 (8.9%) 10 (12.3%)
N3 0 0 0 5 (3.3%) 3 (5.4%) 11 (13.6%)
CD4:CD8>3.5 4/52 (7.7%) 9/56 (16.1%) 14/76 (18.4%) 21/86 (24.4%) 11/37 (29.7%) 52/67 (77.6%)
CD4:CD8>10 1/52 (1.9%) 2/56 (3.6%) 2/76 (2.6%) 9/86 (10.5%) 2/37 (5.4%) 35/67 (52.2%)
CD4þCD7->15% 2/35 (5.7%) 12/36 (33.3%) 9/33 (27.3%) 18/57 (32.1%) 7/22 (31.8%) 32/36 (88.9%)
CD4þCD7->40% 0/35 2/36 (5.6%) 3/33 (9.1%) 8/57 (14.0%) 0/22 22/36 (61.1%)
CD4þCD26->15% 10/35 (28.6%) 16/36 (44.4%) 14/33 (42.4%) 31/57 (54.4%) 14/22 (63.6%) 33/36 (91.7%)
CD4þCD26->30% 1/35 (2.9%) 9/36 (25.0%) 6/33 (18.2%) 17/57 (29.8%) 6/22 (27.8%) 27/36 (75.0%)
Raised LDH 5/85 (5.9%) 13/80 (16.3%) 8/76 (10.5%) 33/114 (29.0%) 15/49 (30.6%) 52/78 (66.7%)
Identical TCR blood clone 1/20 (5.0%) 3/31 (9.7%) 5/31 (16.1%) 14/53 (26.4%) 5/24 (20.8%) 26/43 (60.4%)
Abbreviations: B0, absolute counts of either CD4þCD7-or CD4þCD26-are <250/mL cells; B1, CD4þCD7-or CD4þCD26-counts are between
250/mLe<1000/mL cells; B2, CD4þCD7-cells or CD4þCD26-cells or other aberrant phenotype 1000/mL in the presence of a relevant T-cell clone
in blood; MF, mycosis fungoides; SS, Se´zary syndrome; PROCLIPI, Prospective Cutaneous Lymphoma International Prognostic Index.
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CD4þCD26-percentage was 30% in 15/373 (4%) of
patch, plaque/tumour patients (including 1.4% with
patch, 7.3% with plaque and 7% with tumour disease
compared with 70% in erythroderma).
Rare cases of B2 in patch/plaque MF are described in
the literature, and the prognostic relevance is not known
compared with patch/plaque patients with lower or no
blood involvement [14e17]. A study of 6 patients ful-
filling B2 without erythroderma, 1 of 2 patients with T1-
stage MF had died, but there were no disease-specific
deaths during a median follow-up of 9 years [16].
Conversely, a recent study from the Mayo clinic of 16
patients diagnosed between 1976 and 2010 with CTCL
having B2 but without erythroderma (most commonly
patches and plaques [n Z 12] had a median time from
identification of B2 to death of just 3.6 years; range,
0.5e8.7 years) which was similar survival to their SS
patients p Z 0.08 [17].
The PROCLIPI study which opened in 2015 is pro-
spectively collecting, at diagnosis and follow-up, data on
patients with MF/SS and will determine the prognostic
significance of blood-class with time. Preliminary
PROCLIPI data from Europe similarly identified a
small percentage of patients with patch/plaque or
tumour to have B1 (5.9%) and B2 (1.3%). Blood
involvement was present at low levels through T class
T1-T3 with no significant trend for increased blood
involvement with T1-T3 class and was significantly
lower than T4 (erythrodermic patients) with 22.2% B1
and 49.4% B2. Table 2 reports preliminary PROCLIPI
data from Europe showing blood-class, nodal-class, flow
cytometry, serum LDH and blood T-cell clone accord-
ing to T-class. According to the revised staging in 2007,
patch/plaque and tumour patients with B2 are staged
IVA1 with implications for treatment and survival, butno previous study has prospectively studied the signifi-
cance of blood-class in patch/plaque or tumour disease
at diagnosis and through the course of the disease, and it
is unclear how blood involvement/class fluctuates with
time/disease course. Such that the quantification of
blood involvement may not be important for staging or
therapeutic response in patch/plaque or tumour disease.
The percentage of patients with measurable blood
involvement by flow in skin class T1 through to T3
appears similar suggesting that this flow measurement
may not necessarily reflect severity of MF in skin and as
T-class and stage have prognostic significance then
blood involvement as measured by B0-2 may not have
prognostic relevance in patch/plaque or tumour disease.
Defining blood-class using absolute values of
CD4þCD7-or CD4þCD26-cells, as shown under
PROCLIPI in Table 1, has the advantage of allowing
every patient to be defined a blood-class, but it must be
appreciated that small movements in blood involvement
can allow a blood-class change. At present, blood
response from B1 to B0 is defined as a CR [5], and yet
we have no real insight into the dynamics of blood
involvement in patch/plaque and tumour patients and
how this fluctuates with time, therapy or disease pro-
gression. There are exceptional cases when B2 is found
in patients with patch/plaque or tumours who do not
progress to SS, and we do not understand the clinical or
prognostic consequences of this scenario [10,11,16,17].
Such patients will be followed up prospectively in
PROCLIPI to determine any relevance.
3.3. Blood-class B0-B2 in erythrodermic MF/SS
Staging in erythroderma is determined by blood-class
and the management of patients with erythroderma
is determined by stage [18]. It is therefore of vital
Table 3
Showing the blood tests performed at different sites in according to stage in MF/SS patients.
Principal investigator Site FBC TCR Flow Se´zary count
Scarisbrick Birmingham All All All Erythrodermic
Vakeva Helsinki All All All IIIAeIVB
Estrach Barcelona All IIIAeIV IIIAeIV IIIBeIV
Piris Santander IBeIV IV All All
Servitige Barcelona IBeIV IBeIV IBeIV IBeIV
Papadavid Athens All If flow abnormal IIBeIV IIBeIV
Pujol Barcelona All All All All
Azurdia Liverpool All All All All
Klemke Karlsruhe All IIIAeIV IIAeIV All but CD4þ26- IIIAeIV
Beylot-Barry Bordeaux IIBeIV All IIBeIV select on IB IIBeIV plus
CD158k
Cerroni Graz All Select IIBeIV IIBeIV
Ortiz Madrid IBeIV IBeIV IBeIV None
Dunill Bristol All IIAeIV IIAeIV CD4þ26- only None
Busschots Leuven All select None
Berti Milan All IIBeIV IIIAeIV select IIB IIIAeIV
Vermeer Leiden All IIIAeIV IIIAeIV limited not CD4þ7- CD4þ26- IIIAeIV
Wehkamp Kiel All If flow abnormal All All
Wobser Wu¨rzburg IIBeIV IIBeIV IIBeIV IIBeIV
Bagot Paris All IIBeIV IIBeIV IIBeIV
Stadler Minden All IIBeIV All All
Trautinger St Poelten IIBeIV IIBeIV IIBeIV select on IB, IIA not CD4þCD26- None
Marschalko´ Semmelweis All IBeIV IBeIV select adv for CD4þ7- CD4þ26- IIAeIV
Goldberg Tel Aviv All All All All
Pimpinelli Florence IBeIV IIIeIV IIIeIV None
Nicolay Mannheim All IIBeIV All IIBeIV
Cowan Manchester All None All None
Matin Oxford All All IV Erythrodermic
Bates Southhampton All IIIAeIV IIIAeIV IIIAeIV
MacKay Glasgow All III above If Se´zary cells on film III above
Hodak Petah Tiqva All III above, select on
earlier stages
All All
Quaglino Torino All If flow abnormal IIB to IV All
Abbreviations: MF, mycosis fungoides; SS, Se´zary syndrome.
J.J. Scarisbrick et al. / European Journal of Cancer 93 (2018) 47e56 53importance that blood-class differentiates different
prognostic groups if used to determine patient treatment.
The clinical presentation of erythroderma with
<1000/mL is long recognised and was termed ‘Pre-Se´z-
ary’ by Winkelmann in 1974 [19] and defined as a
chronic, steroid unresponsive erythroderma, lymphade-
nopathy, lymphocytic band at dermo-epidermal junc-
tion and fewer than <1000 circulating Se´zary cells/mm3.
Whilst some of these patients progress to meet the
Se´zary criteria, a number of patients continue a more
benign clinical path [20,21].
A recent large study of 1275 advanced patients
confirmed that erythrodermic CTCL patients have
varying blood tumour burden such that 31% of eryth-
rodermic patients were B0, 20% B1 and 49% B2 [22].
Throughout all advanced stages of MF/SS, there was no
significant difference between survival in B0 or B1 but
survival in B2 was significantly worse pZ 0.021 although
many of these B2 patients had extensive nodal involve-
ment (IVA2) which is known to carry a poor prognosis.
There was no significant difference in median survival or
5-year survival in IIIA, IIIB or IVA1 with mediansurvival in IIIA 61.7 months (5-year survival Z 60.2%),
IIIB 58.2 months (5-year survival Z 55.7%) and IVA1
55.7 months (5-year survival Z 48.3%). Preliminary
analysis of erythrodermic patients in the European
PROCLIPI data set confirms this split with 28.4% of
erythrodermic patients B0, 22.2% B1 and 49.4% B2.
Talpur et al. [10] reported on 1263 MF/SS patients. The
risk of disease progression was significantly greater for
192 B2 patients (including 184 of 188 [97.9%] eryth-
rodermic patients and 8 of 1052 [0.8%] patch/plaque or
tumour patients) as compared with risk of disease pro-
gression in patients with B0e1 in all T-classes
(p< 0.0001). Agar et al. [7] reported on 1502 patients and
found a worse overall survival and disease-specific sur-
vival between B2 compared with B1 (p Z 0.04). The
same data set was used to determine a cutaneous lym-
phoma prognostic index and found B1-2 (where B1 was
>5% circulating Se´zary cells by manual counts) was an
independent prognostic variable, but this was not sig-
nificant using the validation set from MD Anderson [23].
Importantly the data definitions of B1 varies between
these publications Table 1. There are no prognostic
J.J. Scarisbrick et al. / European Journal of Cancer 93 (2018) 47e5654studies comparing B1 as 5% Se´zary cells on manual
counts with B1 defined by flow as an absolute count of
either250/mL e <1000/mL CD4þCD7-or CD4þCD26-
cells.
A study of 84 patients with erythrodermic CTCL
stratified blood involvement into 5 subsets H0-4 and
found a stepwise statistically significant increase in
CTCL-specific deaths where H4 was >10,000/mL Se´zary
cells/[24] suggesting in erythrodermic disease that an
increasing peripheral blood tumour burden may be
inversely proportional to survival in MF/SS. This
finding was replicated in a study of 124 erythrodermic
patients from MD Anderson with median survival in
H0-2 of 7.6 years compared with 2.4 years in H4
(p Z 0.01) [25] and implies a higher blood tumour
burden is a poor prognostic factor.
A recent publication from France reported on 31
erythrodermic stage patients with B0-1 (13 IIIA and 18
IIIB). Six of 18 patients with B1 developed B2 and
fulfilled the criteria for SS, and none with B0, over a
median follow-up of 1.6 years [21]. This agrees with the
conception that some patients with B1 have ‘pre-Se´z-
ary’. A large study from Novelli et al. [26] of flow
cytometry found loss of CD26 to be the most frequent
phenotypic abnormality and confirmed 30% as a
reliable tool when differentiating from inflammatory
erythroderma.
A relevant point of variation between publications is
the definition and requirement for an expanded CD4
population in the definition of B2. This is mentioned but
not defined in the 2007 Staging paper [1] and was based
on an upper limit of normal value of 1600/mL for CD4þ
cells in the Clinical Endpoints paper [5].
The prognostic relevance of erythrodermic patients
with either B0 or B1 is not yet proven prospectively. In
addition, the relevance may be different where histor-
ically B1 was defined as 5% Se´zary cells compared
with B1 defined by flow cytometry. From previously
published data, there was no significant difference in
median survival between IIIA and IIIB patients [13,22].
Patients may fluctuate between blood-class overtime
and with treatment. Some patients with B1 will prog-
ress to SS but others continue with a relatively low
blood tumour burden and may be referred to as
erythrodermic MF. SS is defined as patients with
erythroderma, 1000/mL circulating Se´zary cells and
presence of a relevant T-cell clone. Recent studies have
focused on developing improved diagnostic markers
for SS. A multicentre study of 59 patients with SS
found loss of CD26 in 80% of CD4þ cells or loss of
CD7 in 40% of CD4þ cells could differentiate SS
patients from inflammatory erythroderma with high
specificity [27]. Other possible markers included
DNM3, TWIST1, EPHA4 and PLS3. A further recent
publication suggested KIR3DL2 to be highly specific in
diagnosing SS [28]. Further international studies are
required to determine their value.4. Discussion
4.1. Summary recommendations for blood-class, staging
and blood response criteria
For any staging system to be clinically useful in the man-
agementofpatients; itmust beobjective, reproducible, and
increasing stage should be predictive of patients’ outcome.
Staging criteria inMF/SS were revised more than 10 years
ago, and since this time, further information on the prog-
nostic importance of stage has been published in several
large studies [7,10,22]. Whilst we await our large-scale in-
ternational prospective PROCLIPI study to determine the
prognostic importance of TNMB and other biomarkers,
we propose the following considerations should be applied
to the current staging and clinical end-points.
1) Recommendations for defining blood class
Flow cytometry is our recommended method of
measuring blood involvement in all stages of MF and
SS. To ensure all patients are designated a blood-class,
there is a requirement to select a cut off between classes.
We propose that this is determined using absolute flow
counts of CD4þCD7-or CD4þCD26-. This will allow
blood-class to be comparative between centres for pro-
spective testing.
For staging patch/plaque or tumour patients, B2
should be tracked prospectively to determine if this is of
clinical significance at present these patients are assigned
stage IVA1 [1].
2) Definition of Sezary syndrome
Sezary syndrome (stage IVA1 and above) should be
defined as patients with erythroderma, B2 blood
involvement and a circulating TCR clone identical to
skin. Bone marrow involvement is not a defined criteria
for SS as its’ relevance is not currently understood. It is
not routinely performed in centres. The prognostic
relevance of eythrodermic patients with minor blood
involvement (B0-1) (stage IIIA/B) is not yet known.
3) Blood response criteria
The relevance of blood-class in MF/SS is not only
related to stage but also contributes to the response to
therapy in clinical trials. For response criteria in blood,
we suggest that for a complete response, B2 should
improve to B0 as B2 to B1 may not be clinically relevant.
Improvement from B1 to B0 should not meet CR as the
significance of this is not yet known. A PR should be
considered as a 50% reduction in blood tumour burden
only in those with B2 because the relevance of B0/B1 is
not known. Fluctuations between B0 and B1 should not
be included as treatment response as movement between
B0 and B1 does not alter management in erythroderma
Table 4
Recommendations for blood response criteria for MF/SS.
Response Definition Change from end-points 2011
Complete response (CR)  B0, B1 no CR possible
 B2 to B0
B1 to B0 no longer considered CR
Partial response (PR)  B0, B1 no PR possible
 B2 as 50% reduction in absolute count
No change
Stable disease (SD)  B0,B1, B2 fails to attain CR, PR or PD No change
Progressive disease (PD)  B0 or B1 to B2 with an increase in
absolute counts of 50%
 B2 with an increase in absolute counts of 50%
 Loss of response with an increase in
absolute counts 1000/mL and 50% from nadir
Remove the need for at least 5000
neoplastic cells/mL for PD
Relapse  Increase in absolute counts of 1000/mL in those with CR Relapse not possible in B0-1 as no
CR in these patients
Abbreviations: Absolute count, absolute flow counts using CD4þCD7-, CD4þCD26-or other aberrant phenotype; B0, absolute counts of either
CD4þCD7-or CD4þCD26-are<250/mL cells; B1, CD4þCD7-or CD4þCD26-counts are between 250/mLe<1000/mL cells; B2, CD4þCD7-cells or
CD4þCD26-cells or other aberrant phenotype 1000/mL in the presence of a relevant T-cell clone in blood.
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clinically relevant, and low-level blood involvement with
CD4þ7- or CD4þ26-cells are also seen in benign der-
matoses. Hence, we propose B1 to B0 should not be
recorded as a CR for any patients and B1-B0-B1 should
not be considered a relapse Table 4. We also propose the
elevated number of neoplastic cells for progressive disease
(PD) as >5000/mL should be lowered to 1000/mL plus a
50% increase from baseline or nadir for ‘loss of
response’ Table 4. A possible 500% increase in blood
tumour burden to 5000/mL before PD is reached was used
from the CLL definition [5,29] but is deemed too high
and not in line with response criteria for PD in skin
(>25%), lymph nodes (>50%) or viscera (>50%). It is
important to recognise within the clinical trial setting that
blood response criteria needs to be evaluated in relation
to skin responses as part of the global response assess-
ment [5]. Future studies might provide improved tools for
identifying and quantifying tumour cells. Combined with
longitudinal clinical studies, this might determine better
cut off values for blood-class.
4.2. Recommendations
 Either CD4þCD7-or CD4þCD26-may be used for
measuring B-class where B0<250/mL (250 SI units),
B1Z 250/mle<1000/mL (250e1000 SI units) and B21000/
mL (1000 SI units) plus a relevant T-cell blood clone.
 Movement between B0 and B1 should not be considered in
the treatment response criteria
 In B2, an increase in absolute counts of 50% should be
considered PD without the current requirement for 5000/
mL
 The significance of B2 in patch/plaque/tumour MF is un-
known, and patients should be tracked
5. Conclusion
Consistency in flow definition for blood-class is critical
for evaluation of patient outcome and must be anobjective measurement. Our current knowledge of the
implications of ’minor’ blood involvement (B0-1) is
rudimentary and should not be used as a primary indi-
cator to change patients’ treatments.Funding
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